Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Epanova vs Lovaza Under Low-Fat and High-Fat Conditions
NCT01208961Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia (2 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours, Area Under the Plasma Concentration-time Curve From 0 to Infinity and 1 more. Started Sep 2010; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT01208961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01208961.